Biotechnology company Aboundbio Inc said on Tuesday that its team has discovered human monoclonal antibodies with exceptional neutralizing activity in the laboratory against SARS-CoV-2, the virus that causes COVID-19.

The human monoclonal antibodies with neutralizing activity in the laboratory against SARS-CoV-2 was discovered by D. Dimitrov, PhD and J. Mellors, MD, co-founders of AboundbioInc, USA. Antibody production and clinical development for regulatory approval and commercialization in the MENA and ASEAN regions of the world are proceeding under a license agreement with SaudiVax of Saudi Arabia.

Aboundbio stated that the antibodies were selected out of billions of others using extraordinarily large antibody libraries. The ultra-specificity of the antibodies has been shown by the absence of binding to more than 5,300 proteins in the human cell surface proteome. The antibodies do not increase infection in cell culture models of "antibody-dependent enhancement," a general concern about antibody for infectious diseases. The lead antibodies are effective at low doses in mouse and hamster models of SARS-CoV-2 infection, concluded the company.